An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2025-07-23
Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Conditions
- Ophthalmic Safety in Patients With Breast Cancer
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 130 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-04
- Primary Completion
- 2027-07-06
- Completion
- 2027-07-06
Countries
- United States
- Argentina
- Belgium
- Brazil
- Canada
- Chile
- France
- Israel
- Italy
- Mexico
- Poland
- Portugal
- South Korea
- Spain
Study Locations
More Related Trials
-
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
NCT06075758 ·Status: COMPLETED
-
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
NCT03099174 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332 ·Status: RECRUITING ·Phase: PHASE3
-
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
NCT06795503 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
AZD9496 First Time in Patients Ascending Dose Study
NCT02248090 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
NCT06776861 ·Status: RECRUITING
-
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
NCT06332131 ·Status: ENROLLING_BY_INVITATION
-
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
NCT04075604 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
NCT07037199 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
NCT04148911 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan for Advanced and Metastatic Breast Cancer
NCT03562390 ·Status: UNKNOWN ·Phase: PHASE2
-
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
NCT00971945 ·Status: COMPLETED ·Phase: PHASE2
-
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
NCT07180693 ·Status: RECRUITING
-
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
NCT06962969 ·Status: COMPLETED
-
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
NCT06508216 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
NCT05916755 ·Status: RECRUITING
-
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
NCT03195192 ·Status: COMPLETED ·Phase: NA
-
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
NCT03462251 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
NCT04437160 ·Status: RECRUITING ·Phase: PHASE2
-
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
NCT01078662 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
NCT06810492 ·Status: NOT_YET_RECRUITING ·Phase: NA